Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir-Reference-Cited by-同舟云学术

Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir

Published:2018-07 Issue:7 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Focà Emanuele¹^ORCID,Calcagno Andrea²,Bonito Andrea¹,Cusato Jessica²,Domenighini Elisabetta¹,D'Avolio Antonio²^ORCID,Quiros Roldan Eugenia¹,Trentini Laura²,Castelnuovo Filippo¹,Di Perri Giovanni²,Castelli Francesco¹,Bonora Stefano²

Affiliation:

1. Unit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, University of Brescia and Spedali Civili General Hospital, Brescia, Italy

2. Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Turin, Italy

Abstract

ABSTRACT Atazanavir-ritonavir concentrations change over time during pregnancy in HIV-positive patients; the impact of genetic variants is unknown. Twenty patients were enrolled in this study; plasma and intracellular concentrations of antiretrovirals were measured, in addition to single-nucleotide polymorphisms in transport-related genes. Linear logistic regression showed that genetic variants in organic-anion-transporter-1B1- and pregnane-X-receptor-encoding genes affected third-trimester atazanavir exposure. In this prospective study, genetic variants partially explained the observed interpatient variability in third-trimester exposure to antiretrovirals.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00309-18

Reference26 articles.

1. World Health Organization. 2013. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. World Health Organization, Geneva, Switzerland.

2. The intracellular pharmacology of antiretroviral protease inhibitors

3. Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action

4. Intracellular Accumulation of Human Immunodeficiency Virus Protease Inhibitors

5. The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients;Crommentuyn KM;Antivir Ther,2004

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiretroviral Therapy in Pregnancy: A 2023 Review of the Literature;Current HIV/AIDS Reports;2024-01-26

2. HIV in pregnancy: Mother-to-child transmission, pharmacotherapy, and toxicity;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2021-10

3. Pharmacokinetics of HIV therapies in pregnant patients: an update;Expert Opinion on Drug Metabolism & Toxicology;2020-04-19